Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

Recruiting Observational Study
Alport Syndrome Hereditary Kidney Disease Pediatric Kidney Disease Thin Basement Membrane Disease Familial Benign Hematuria
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Observational
Participants needed
800 (estimated)
Sponsor
University Hospital Goettingen · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The hereditary type IV collagen disease Alport syndrome leads to kidney failure early in life. Currently there are no specific medications approved for treatment, however, several therapies have been evaluated preclinically and could improve outcome. For that reason, this non-interventional, observational study investigates, if medications (1) delay disease progression; (2) delay time to kidney fa…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Diagnosis of Alport syndrome (AS) by kidney biopsy or mutation analysis (or both). Any type of genetic variant is accepted for X-linked, autosomal or digenic Alport syndrome (COL4A3, 4 or 5 genes). Exclusion criteria: Patients not willing to give informed consent. Patient wit…
Contacts

Oliver Gross, MD

+49-551-39-

gross.oliver@med.uni-goettingen.de

CONTACT